Abstract. Metaiodobenzylguanidine (MIBG) imaging is used in the diagnosis, staging and follow-up of virtually every case of neuroblastoma seen at our institution. Normal sites of MIBG uptake include the liver and therefore difficulties have been predicted and encountered in the diagnosis of hepatic neuroblastoma due to inability to separate abnormally increased tracer deposition from normal hepatic activity. We reviewed every MIBG (1123 and 1131) study performed at our pediatric hospital over a 4 year period encompassing 88 patients, 67 of whom had biopsy proven neuroblastoma. Hepatic findings onMIBG studies were compared with concurrent abdominal CT and US studies in all 67 patients. The clinical records of all patients with abnormal MIBG scans or abnormal CT or US studies of the liver were also reviewed. Eight patients were found to have abnormal liver findings on one or more imaging studies (MIBG, CT, or US). There were 3 true positive MIBG studies, one of which was an early study in a patient who later went on to have one of the false positive studies. Two patients had false positive MIBG scans for liver neuroblastoma. MIBG failed to detect liver involvement in 4 patients.
We also discuss whether incorrect assessment of hepatic involvement by MIBG liver scintigraphy resulted in incorrect or delayed diagnosis or staging and describe the clinical and anatomic settings in which potential pitfalls are most likely to be encountered.
Materials and methods
All MIBG studies (I 123 and I TM) performed on the pediatric population at our children's hospital from January, 1988 to November, 1992 were reviewed. Eighty-eight children had one or more studies. Sixtyseven children had pathologically proven neuroblastoma. All abdominal computed tomography (CF) and ultrasound (US) interpretations on those 67 patients were reviewed noting the presence of abnormal findings in the liver. Hepatic findings on MIBG and concurrent CT and US studies were compared. Clinical information and medical records were reviewed on all patients with abnormal MIBG or abnormal CT or US studies of the liver.
Results
Eight patients had abnormal liver findings on one or more of these studies (MIBG, CT, US). MIBG hepatic uptake in the liver was abnormal in 5 patients. Of these, 3 were confirmed cases of hepatic involvement by neuroblastoma. CT detected 5 of 6 cases of hepatic neuroblastoma as well as abnormalities not due to neuroblastoma. Ultrasound was used in 2 patients, both of whom had hepatic neuroblastoma shown at sonography, including one case where MIBG and CT were not interpreted as abnormal. Fiftynine of the 67 patients (88 %) had no evidence of liver involvement with neuroblastoma using any modality (MIBG, CT or ultrasound) . Liver biopsies were not routinely performed and for the purposes of this study, these patients were considered to have true negative MIBG studies of the liver.
Three patients had true positive MIBG studies, two with stage IV-S disease ( Fig. 1) and one with stage IV disease where several focal liver metastases were detected with I TM MIBG as well as with CT. Two patients had false positive MIBG scans for neuroblastoma in the liver. One of these was a patient with proven diffuse and progressive hepatic candidiasis which resulted in a very mottled pattern of uptake in his enlarged liver (Fig.2) . It could not be determined whether the abnormal image was due to multiple areas of increased uptake due to metastatic loci of neuroblastoma or whether there were actually multiple areas of decreased uptake where abscesses had formed, thereby distorting the normal homogeneous liver uptake. The other false positive MIBG study occurred in a patient with treated IV-S disease in whom an I TM MIBG scan initially showed diffusely abnormal liver activity (one of the true positives in our series) (Fig. 3) . However the patient eventually improved with only patchy areas of mildly increased uptake in the right lobe. The CT scan corroborated this observation, but open biopsy of the suspicious area revealed only ganglioneuroma with no malignant cells detected on numerous histologic sections.
MIBG studies failed to detect liver involvement by neuroblastoma in four patients. One false negative MIBG study was felt to be due to a change in the tumor's biological behavior which resulted in decreased uptake of the agent. In this patient, CT studies documented progressive disease, eventually leading to the patient's death, while serial I TM MIBG studies showed gradual diminution in uptake, appearing normal three weeks before the patient died (Fig.4) . A second false negative MIBG study occurred with recurrent disease which had directly invaded the undersurface of the liver. In this case, I TM MIBG could not distinguish between hepatic invasion Fig.4a, b. 3-year-old female initially diagnosed with stage III disease status post chemotherapy, surgery and X-ray therapy, a I TM MIBG scan shows normal liver, heart (H) and bladder (B) activity and was read as normal, b CT shows bulky abdominal disease not detected by MIBG. Liver images (not shown) were suspicious for focal disease Fig.5a , b. Patient diagnosed at 18 months with abdominal mass and stage III disease. Status post chemotherapy, surgery and X-ray therapy with recurrent abdominal mass at 20 months of age. a I TM MIBG scan shows increased activity in right upper abdomen (arrows) but distinction between abdominal disease and liver invasion cannot be made. b CT shows tumor invading under surface of liver Fig.6a --e. 2-months-oldmalewithhepatomegaly. a IlZ3MIBGscan shows normal uptake in salivaryglands, heart (H), and bladder (B). The liver was felt to be within normal limits, b Sagittal US shows mottled hepatic echotexture, Two of the many diffuse hypoechoic lesions are labelled with arrows. K, kidney, c 7.5 MHz linear array transducer shows the anterior 3 cm of the liver with multiple hypoechoic nodules between I and 3 mm in diameter. Four nodules are labelled, d Enhanced CT shows subtle inhomogeneity but was not read as abnormal, e Delayed CT images again suggest inhomogeneity but not unlike the appearance of the normal spleen and paraspinal muscles Fig.7a, b . Male patient presented with a right abdominal mass and stage IV disease, a Ii3I MIBG scan shows subtle increased uptake in right upper quadrant (arrows). H, heart; B, bladder, b CT shows multiple low attenuation lesions in liver, each less than 2 cm. Low density in posterior right lobe represents superior aspect of adrenal primary tumor mass and recurrent abdominal bulky disease (Fig. 5) . A third false negative occurred with disseminated hepatic infiltration in a 2-month-old child with stage IV-S disease in whom there was no other tumor site. Uniformly increased 1123 MIBG activity throughout the liver was not prospectively considered abnormal. Sonography showed a diffuse inhomogeneous echo texture suggesting infiltrating malignancy, which was proven at laparotomy. CT scan done at the time of presentation was likewise not prospectively interpreted as definitely abnormal although retrospectively, when compared to a study done six months later when the patient was in complete remission (achieved without therapy), the liver had been subtly inhomogeneous with some distortion of the normal hepatic vascular architecture (Fig. 6) . The fourth false negative case was an I TM MIBG study which failed to detect several small focal deposits in the liver (each under 2 cm in diameter) despite showing the primary lesion in the adrenal fossa (Fig. 7) .
Discussion
MIBG is an excellent imaging agent for detection, staging, and monitoring of neuroblastoma [1, 4] . However, false negative MIBG studies of the liver do occur and are usually due to the difficulty of detecting abnormally increased uptake against the normal hepatic background activity. This can make detection of diffuse disease seen in stage IV-S patients problematic, although 2 of 3 patients with IV-S disease did have prospective diagnoses of liver involvement made on MIBG scans. Detecting small lesions, even when focal, can be difficult and was a cause of one false negative MIBG study. This limitation in spatial resolution also resulted in the inability to detect hepatic invasion by recurrent primary disease, although concurrent CT scanning clearly showed the anatomic detail necessary to make the correct diagnosis. In the case of changing uptake of MIBG over time, clinical and CT data clearly showed disease progression despite decreasing uptake of MIBG. In none of the four cases was there any delay in the proper diagnosis or staging of the patient's disease.
Our experience with false positives points out other limitations of MIBG scans for liver involvement [4] . Diffuse microabscesses of candidiasis were clinically likely but could not be confidently distinguished from multiple deposits of metastatic disease on MIBG scans. Uptake of MIBG by ganglioneuroma has been reported but is decidedly uncommon [4] . This was one instance where a biopsy was performed to evaluate a persistently abnormal MIBG study due to benign disease.
It has been noted previously that the sensitivity of MIBG for detection of hepatic disease is significantly lower than for detection elsewhere in the abdomen, chest and skeleton [4] . Our experience suggests that MIBG scan alone should not be relied upon for detecting or excluding hepatic neuroblastoma. Once MIBG images are correlated with the clinical picture and the results of higher resolution anatomic imaging studies, few errors and no significant delays in staging or diagnosis should occur.
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Causes of false negative MIBG studies for hepatic involvement which we encountered include inability to distinguish subtle diffuse IV-S disease throughout the liver against normal background uptake, difficulty in resolving small focal lesions, and tumors which do not take up tracer.
